KR101707669B1 - 약제-내성 종양에서 화학요법제 활성을 증강시키는 ｏｎ01910.ｎａ - Google Patents

약제-내성 종양에서 화학요법제 활성을 증강시키는 ｏｎ01910.ｎａ Download PDF

Info

Publication number
KR101707669B1
KR101707669B1 KR1020107025808A KR20107025808A KR101707669B1 KR 101707669 B1 KR101707669 B1 KR 101707669B1 KR 1020107025808 A KR1020107025808 A KR 1020107025808A KR 20107025808 A KR20107025808 A KR 20107025808A KR 101707669 B1 KR101707669 B1 KR 101707669B1
Authority
KR
South Korea
Prior art keywords
delete delete
cancer
chemotherapeutic agent
gemcitabine
nucleotide analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107025808A
Other languages
English (en)
Korean (ko)
Other versions
KR20100137570A (ko
Inventor
안토니오 지메노
마누엘 메디나 히달고
Original Assignee
더 존스 홉킨스 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 존스 홉킨스 유니버시티 filed Critical 더 존스 홉킨스 유니버시티
Publication of KR20100137570A publication Critical patent/KR20100137570A/ko
Application granted granted Critical
Publication of KR101707669B1 publication Critical patent/KR101707669B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020107025808A 2008-04-17 2008-04-17 약제-내성 종양에서 화학요법제 활성을 증강시키는 ｏｎ01910.ｎａ Expired - Fee Related KR101707669B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/005104 WO2009128805A1 (en) 2008-04-17 2008-04-17 On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors

Publications (2)

Publication Number Publication Date
KR20100137570A KR20100137570A (ko) 2010-12-30
KR101707669B1 true KR101707669B1 (ko) 2017-02-16

Family

ID=41199352

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020107025808A Expired - Fee Related KR101707669B1 (ko) 2008-04-17 2008-04-17 약제-내성 종양에서 화학요법제 활성을 증강시키는 ｏｎ01910.ｎａ

Country Status (10)

Country Link
US (2) US8962614B2 (enExample)
EP (1) EP2271339A4 (enExample)
JP (1) JP5479453B2 (enExample)
KR (1) KR101707669B1 (enExample)
CN (1) CN102056607B (enExample)
AU (1) AU2008354754B2 (enExample)
CA (1) CA2721722C (enExample)
NZ (1) NZ588749A (enExample)
RU (1) RU2476239C2 (enExample)
WO (1) WO2009128805A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2721722C (en) * 2008-04-17 2015-12-08 The Johns Hopkins University On01910.na enhances chemotherapeutic agent activity in drug-resistant tumors
ES2864681T3 (es) * 2012-12-07 2021-10-14 Onconova Therapeutics Inc Tratamiento del cáncer hematológico refractario a un agente contra el cáncer
US9566280B2 (en) 2014-01-28 2017-02-14 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
DK3138555T3 (da) 2014-04-30 2020-12-14 Fujifilm Corp Liposomsammensætning og fremgangsmåde til fremstilling heraf
WO2016137235A2 (ko) 2015-02-25 2016-09-01 (주)바이오니아 마이크로 rna를 유효 성분으로 포함하는 암 치료용 약학 조성물
US10669302B2 (en) * 2015-08-28 2020-06-02 Zhejianf Hisun Pharmaceutical Co., Ltd. Crystal form of fludarabine phosphate, preparation method therefor, and application thereof
CN109232403A (zh) * 2017-07-10 2019-01-18 亚宝药业集团股份有限公司 作为蛋白激酶抑制剂的酰胺类前药衍生物
JP7364561B2 (ja) * 2018-06-20 2023-10-18 富士フイルム株式会社 ゲムシタビンを内包するリポソーム組成物および免疫チェックポイント阻害剤を含む組合せ医薬
TWI826738B (zh) * 2019-10-21 2023-12-21 奈威生技股份有限公司 癌症治療方法
WO2023158514A1 (en) 2022-02-18 2023-08-24 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128777A1 (en) 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
US20070203210A1 (en) 2006-02-27 2007-08-30 John Frederick Boylan Thiazolyl-benzimidazoles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2321454A (en) * 1997-01-24 1998-07-29 Norsk Hydro As Gemcitabine esters and amides
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20070197538A1 (en) * 2004-10-07 2007-08-23 Mark Nesbit Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
US20090306207A1 (en) * 2005-01-05 2009-12-10 Reddy M V Ramana Treatment of Drug-Resistant Proliferative Disorders
WO2008027049A1 (en) * 2006-08-30 2008-03-06 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
JP5528806B2 (ja) * 2006-10-12 2014-06-25 アステックス、セラピューティックス、リミテッド 複合薬剤
US20080279874A1 (en) * 2007-05-07 2008-11-13 Wyeth Compositions and methods for modulation of plk1 kinase activity
CA2721722C (en) * 2008-04-17 2015-12-08 The Johns Hopkins University On01910.na enhances chemotherapeutic agent activity in drug-resistant tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128777A1 (en) 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
US20070203210A1 (en) 2006-02-27 2007-08-30 John Frederick Boylan Thiazolyl-benzimidazoles

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Cell. 2005. Vol. 7, pp. 275-286*

Also Published As

Publication number Publication date
CA2721722C (en) 2015-12-08
AU2008354754B2 (en) 2014-09-11
US20150209381A1 (en) 2015-07-30
JP5479453B2 (ja) 2014-04-23
EP2271339A4 (en) 2011-09-28
NZ588749A (en) 2012-06-29
CN102056607A (zh) 2011-05-11
JP2011518153A (ja) 2011-06-23
KR20100137570A (ko) 2010-12-30
US20110201675A1 (en) 2011-08-18
RU2476239C2 (ru) 2013-02-27
AU2008354754A1 (en) 2009-10-22
RU2010145048A (ru) 2012-05-27
EP2271339A1 (en) 2011-01-12
WO2009128805A1 (en) 2009-10-22
CA2721722A1 (en) 2009-10-22
CN102056607B (zh) 2014-07-30
US8962614B2 (en) 2015-02-24
US9545418B2 (en) 2017-01-17

Similar Documents

Publication Publication Date Title
KR101707669B1 (ko) 약제-내성 종양에서 화학요법제 활성을 증강시키는 ｏｎ01910.ｎａ
JP6963545B2 (ja) 癌を治療するための併用療法
US12083136B2 (en) Combination of BCL-2/BCL-XL inhibitors and chemotherapeutic agent and use thereof
JP2011173928A (ja) 癌処置のためのエポチロンの使用
KR20220151027A (ko) Ｍｄｍ２ 억제제의 간헐적 투여
US7851443B2 (en) Combination comprising combretastatin and anticancer agents
TW201919616A (zh) 用於治療ｔ－ｐｌｌ的化合物
EP3681503A1 (en) Protein kinase c inhibitors for treatment of uveal melanoma
US20210386826A1 (en) Combination for Treating Cancer
US20200297743A1 (en) Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof
KR20140125644A (ko) 종양 전이의 저해에 있어서의 시스테아민 및 그의 유도체의 용도
WO2021048417A1 (en) Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma
JP2009519318A (ja) アザキサントンを用いる腫瘍の治療方法
PL201289B1 (pl) Zastosowanie pochodnej a-halogenoakryloilodystamycyny do wytwarzania leku do leczenia nowotworów u ludzi
AU2023360058A1 (en) Method of increasing immune cell activation and/or treating cancer using dibenzoxazepinones.
WO2025232723A1 (en) Treatment method with focal adhesion kinase inhibitor
TW202317128A (zh) 治療化療相關的胃腸道副作用的化合物和方法
US10434086B2 (en) Combination therapies with curaxins
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma
JP2022543021A (ja) がんを処置する方法及び使用
WO2007013696A1 (ja) ６’－アミジノ－２’－ナフチル４－グアニジノベンゾエート又はその塩を含んでなる抗腫瘍剤
US20210355223A1 (en) Combinations for Treating Cancer
HK1117750A (en) Triazine compounds and compositions thereof for the treatment of cancers

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

St.27 status event code: A-3-4-F10-F13-rex-PB0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20200130

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20250211

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20250211